EFFECTS OF CYP2C9☆13 ALLELE ON THE PHARMACOKINETICS OF IRBESARTAN

被引：0
|
作者：
Park, J., I [1 ]
Choi, C., I [1 ]
Bae, J. W. [1 ]
Jang, C. G. [1 ]
Lee, S. Y. [1 ]
机构：
[1] Sungkyunkwan Univ, Sch Pharm, Seoul, South Korea
来源：
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2011年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：64 / 64
页数：1
相关论文
共 50 条
  • [41] Allele and genotype frequency of CYP2C9 in Tamilnadu population
    Adithan, C
    Gerard, N
    Vasu, S
    Balakrishnan, R
    Shashindran, CH
    Krishnamoorthy, R
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (8-9) : 707 - 709
  • [42] Siponimod and CYP2C9 Allele Prevalence Among Blacks
    Liu, Michelle
    Obeng, Aniwaa Owusu
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (04): : 429 - 431
  • [43] CYP2C9 polymorphisms and CYP2C9*2 genotyping primers
    Goldstein, JA
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (04) : 409 - 410
  • [44] Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics
    Kirchheiner, J
    Müller, G
    Meineke, I
    Wernecke, KD
    Roots, I
    Brockmöller, J
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (05) : 459 - 466
  • [45] Effects of CYP2C9*3 and CYP2C9*13 on Diclofenac Metabolism and Inhibition-based Drug-Drug Interactions
    Zi, Jing
    Liu, Duan
    Ma, Pingping
    Huang, He
    Zhu, Juanli
    Wei, Dongqing
    Yang, Jin
    Chen, Chao
    DRUG METABOLISM AND PHARMACOKINETICS, 2010, 25 (04) : 343 - 350
  • [46] Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects
    Sekino, K
    Kubota, T
    Okada, Y
    Yamada, Y
    Yamamoto, K
    Horiuchi, R
    Kimura, K
    Iga, T
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (8-9) : 589 - 592
  • [47] Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects
    Kazuishi Sekino
    Takahiro Kubota
    Yuko Okada
    Yasuhiko Yamada
    Koujirou Yamamoto
    Ryuya Horiuchi
    Kenjirou Kimura
    Tatsuji Iga
    European Journal of Clinical Pharmacology, 2003, 59 : 589 - 592
  • [48] Consequences of CYP2C9 polymorphisms on flurbiprofen pharmacokinetics.
    Lee, CR
    Pieper, JA
    Frye, RF
    Hinderliter, AL
    Blaisdell, JA
    Goldstein, JA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P62 - P62
  • [49] The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan
    Kobayashi, Mariko
    Takagi, Miho
    Fukumoto, Kyoko
    Kato, Ryuji
    Tanaka, Kazuhiko
    Ueno, Kazuyuki
    DRUG METABOLISM AND PHARMACOKINETICS, 2008, 23 (02) : 115 - 119
  • [50] CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response
    Miners, J
    PHARMACOGENETICS, 2002, 12 (02): : 91 - 92
12345